WEREWOLF THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $44.8M | $56.4M | $41.8M | $53.8M | $35.3M | $16.6M |
| SG&A Expense | — | $15.8M | $19.0M | $18.7M | $18.7M | $14.8M | $5.8M |
| Operating Income | — | $-60.7M | $-73.6M | $-40.5M | $-56.1M | $-50.1M | $-22.4M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | $5.3M | $3.3M | $3.1M | $0 | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | — | — |
| Net Income | — | $-60.8M | $-70.5M | $-37.4M | $-53.8M | $-50.0M | $-15.0M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.32 | $-1.63 | $-1.05 | $-1.86 | $-10.94 | $-1.56 |
| EPS (Diluted) | — | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 | $-1.56 |
| Shares Outstanding (Basic) | 48.6M | 46.0M | 43.3M | 35.6M | 28.9M | 18.5M | 18.1M |
| Shares Outstanding (Diluted) | 48.6M | 46.8M | 43.9M | 35.6M | 28.9M | 18.5M | 18.1M |
| Dividends Per Share | — | — | — | — | — | — | — |